New search | Conferencedetail
mail
Print view
 
 

3rd TIGIT Axis Therapies

Evvnt Promotion / evvnt
-
07.12.2022 - 08.12.2022  Virtual Event, USA
Time: 8:00 am to 5:00 pm
 
Conference themes
As immuno-oncology drug development transforms cancer treatment paradigms, preclinical and clinical data continues to demonstrate that the TIGIT axis blockade, particularly in combination with other immune checkpoint inhibitor partners, has strong efficacy. Despite recent clinical setbacks, and with at least 15 anti-TIGIT axis drugs in active clinical development, TIGIT axis targeting remains a promising treatment approach.
Scientific Society
Hanson Wade
Notes
Speakers: Murali Ramachandra, Chief Executive Officer, Aurigene Discovery Technologies, David Wald, Associate Professor, Case Western Reserve University, Leonie Meima, Vice President Business Development, Coherus Biosciences
 

Enquiries and Registration:

https://go.evvnt.com/1234464-2?pid=4832
Ms. Ellie Saunders
 
Categories
Oncology
Languages
English
Congress fees
Conference Only - Industry Pricing - On the Day : USD 2299.00, Conference Only - Academic Pricing - On the Day: USD 2099.00, Conference Only - Service and Solution Provider Pricing - On the Day: USD 2799.00
Organizer contact info
83 Great Titchfield Street
W1W 6RH London
United Kingdom
 
"Going International promotes access to education and training for all regardless of social, geographic and national borders."

newTreeCentro per la Formazione Permanente e l'Aggiornamento del Personale del Servizio SanitarioÄrzte der WeltCharité International AcademyAGEM - Arbeitsgemeinschaft Ethnologie und MedizinÄrztekammer für WienÖsterreichische Akademie der ÄrzteÖsterreichisches Rotes Kreuz